Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. GENB
GENB logo

GENB Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Generate Biomedicines Inc (GENB) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
12.030
1 Day change
-3.91%
52 Week Range
--
Analysis Updated At
2026/03/20
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

Generate Biomedicines Inc (GENB) is not a strong buy at the moment due to lack of significant trading trends, absence of news catalysts, and no proprietary trading signals. For a beginner investor with a long-term strategy, it is advisable to hold off on investing in this stock until more data or positive signals emerge.

Technical Analysis

No trend data is available for technical analysis. The stock closed at $12.29 with a pre-market increase of 1.78% and a regular market increase of 4.06%, but no clear trend can be established.

Positive Catalysts

  • NULL identified. No news or significant trading trends from hedge funds or insiders.

Neutral/Negative Catalysts

  • Lack of trading trends, no recent news, and no proprietary trading signals.

Financial Performance

No financial data available for analysis.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target data available.

Wall Street analysts forecast GENB stock price to rise
0 Analyst Rating
0
Wall Street analysts forecast GENB stock price to rise
0 Buy
0 Hold
0 Sell
0
Current: 12.520
sliders
Low
0
Averages
0
High
0
0
Current: 12.520
sliders
Low
0
Averages
0
High
0
Goldman Sachs
initiated
$26
AI Analysis
2026-03-24
New
Reason
Goldman Sachs
Price Target
$26
AI Analysis
2026-03-24
New
initiated
Reason
Goldman Sachs initiated coverage of Generate Biomedicines with a Buy rating and $26 price target. The company integrates generative AI models with experimental validation via its Generate Platform to produce optimized protein therapeutics, the analyst tells investors in a research note. The firm sees $7B in peak global sales for Generate's lead asset, the TSLP-targeting antibody GB-0895. It believes the Phase 3 severe asthma data around in early 2029 will be in-line to Tezspire.
Piper Sandler
Edward Tenthoff
Overweight
initiated
$24
2026-03-24
New
Reason
Piper Sandler
Edward Tenthoff
Price Target
$24
2026-03-24
New
initiated
Overweight
Reason
Piper Sandler analyst Edward Tenthoff initiated coverage of Generate Biomedicines with an Overweight rating and $24 price target. The company's Generate Platform is a protein discovery engine that integrates AI algorithms with high speed protein synthesis and multiplexed assays to design and validate novel therapeutics, the analyst tells investors in a research note. The firm says Generate's "potential best-in-class" anti-TSLP antibody GB-0895 is currently in two Phase III SOLAIRIA trials in severe asthma.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for GENB
Unlock Now

People Also Watch